First Report, ADA 2015

Featured

ELIXA: No Cardiac Risks, Benefits With Lixisenatide

ELIXA: No Cardiac Risks, Benefits With Lixisenatide

Lixisenatide has neutral effect on heart failure and other cardiovascular outcomes.

ADA 75th Scientific Sessions 2015 Complete Coverage

CMS Competitive Bidding Hurts Medicare Beneficiaries With Diabetes

CMS Competitive Bidding Hurts Medicare Beneficiaries With Diabetes

Competitive bidding reduces access to diabetes supplies and increases mortality for Medicare patients.

Induced Pluripotent Stem Cells: New Tool for Studying Insulin Resistance

Induced Pluripotent Stem Cells: New Tool for Studying Insulin Resistance

Induced pluripotent stem cells offer a new way to study insulin resistance and other metabolic disorders in humans.

Reflecting on 50 Years of Diabetes Research, Management

Reflecting on 50 Years of Diabetes Research, Management

During the past 50 years, diabetes research and management has come a long way, although there is still work to be done.

Glycemic Extremes Impact Brain Function in Teens With Type 1 Diabetes

Glycemic Extremes Impact Brain Function in Teens With Type 1 Diabetes

Activity in certain brain regions of teenagers with type 1 diabetes was increased or decreased with hyperglycemia and hypoglycemia.

Novel Super Long-Acting Insulin, GLP-1 Receptor Agonist Show Promise in Diabetes

Novel Super Long-Acting Insulin, GLP-1 Receptor Agonist Show Promise in Diabetes

PE0139, a super long-acting basal insulin, and PB1023, a weekly GLP-1 receptor agonist, may lead to novel approach to treating diabetes.

Unsupervised Closed Loop Insulin Delivery Feasible for Teens

Unsupervised Closed Loop Insulin Delivery Feasible for Teens

Unsupervised closed loop insulin delivery is safe and feasible in the home setting in teens with type 1 diabetes.

Continuous Glucose Monitoring Reduces Costs, Hypoglycemia Concerns

Continuous Glucose Monitoring Reduces Costs, Hypoglycemia Concerns

Continuous glucose monitoring can reduce costs associated with diabetes and improve quality of life.

Lixisenatide Effective for HbA1c Control, Weight Loss

Lixisenatide Effective for HbA1c Control, Weight Loss

Adding lixisenatide to insulin glargine is comparable to other insulin regimens for controlling HbA1c in type 2 diabetes.

Liraglutide May Reduce Postprandial Hyperglycemia in Closed Loop Setting

Liraglutide May Reduce Postprandial Hyperglycemia in Closed Loop Setting

Adding liraglutide to insulin in a closed loop system may reduce postprandial hyperglycemia as well as insulin requirements, compared with insulin monotherapy.

Trial Testing Tuberculosis Vaccine for Type 1 Diabetes Underway

Trial Testing Tuberculosis Vaccine for Type 1 Diabetes Underway

Researchers will look at effects in people with longstanding disease,

Mothers' Obesity May Pre-Program Children for Obesity, Metabolic Disease

Mothers' Obesity May Pre-Program Children for Obesity, Metabolic Disease

Children may have a higher risk for fat accumulation and insulin resistance if their mothers were obese.

Food Insecurity Affects Diabetes Control in Latino Patients

Food Insecurity Affects Diabetes Control in Latino Patients

Food insecurity has an impact on glycemic control and vegetable consumption in Latino patients with diabetes.

GLP-1 May Modify Brain's Response to Food

GLP-1 May Modify Brain's Response to Food

Gut-based medications like GLP-1 agonists may induce weight loss by reducing cravings and increasing satiety.

FLAT-SUGAR: GLP-1 Agonist Reduced Glycemic Variability Without Changing HbA1c

FLAT-SUGAR: GLP-1 Agonist Reduced Glycemic Variability Without Changing HbA1c

GLP-1 receptor agonist may be able to reduce glycemic variability rather than a prandial insulin.

TECOS: Sitagliptin Not Linked to Increased CV Risk, Heart Failure

TECOS: Sitagliptin Not Linked to Increased CV Risk, Heart Failure

Sitagliptin did not affect rates of cardiovascular complications or heart failure in high-risk patients with type 2 diabetes.

ITCA 650 Safe, Effective in Type 2 Diabetes

ITCA 650 Safe, Effective in Type 2 Diabetes

ITCA 650, which continuously delivers exenatide subcutaneously, yielded improvements in HbA1c and body weight in patients with type 2 diabetes.

Dulaglutide Beat Insulin Glargine in Type 2 Diabetes

Dulaglutide Beat Insulin Glargine in Type 2 Diabetes

Compared with insulin glargine, once-weekly dulaglutide led to superior reductions in HbA1c in patients with type 2 diabetes.

Basal Insulin Peglispro vs. Insulin Glargine in Type 1 Diabetes

Basal Insulin Peglispro vs. Insulin Glargine in Type 1 Diabetes

People with type 1 diabetes treated with basal insulin peglispro vs. insulin glargine had significantly lower HbA1c levels at 26 and 52 weeks.

Fixed-Ratio Combination Insulin Glargine-Lixisenatide Didn't Increase Hypoglycemia

Fixed-Ratio Combination Insulin Glargine-Lixisenatide Didn't Increase Hypoglycemia

Achieving greater HbA1c reductions with fixed-ratio combination insulin glargine/lixisenatide did not increase rates of hypoglycemia.

Dapagliflozin Safe, Effective in Diabetes with Cardiovascular Disease in Long Term

Dapagliflozin Safe, Effective in Diabetes with Cardiovascular Disease in Long Term

Patients with type 2 diabetes and cardiovascular disease may benefit from long-term treatment with dapagliflozin.

Upcoming Meetings

Sign Up for Free e-Newsletters